Ngô Bá Bình (Ngo Ba Binh) is a diagnostics and biotechnology executive who has worked mainly in Vietnam's diagnostics sector. He is the founder of Inogen, which develops molecular diagnostic kits in Vietnam and Australia, and in 2025 he established Inogen Pty Ltd in Queensland.
He was Director of Tâm Việt Medical Equipment and Science Co. Ltd, a Hanoi supplier of diagnostic equipment, and served on the Board of Directors of GENTIS during the period in which the company joined the Eurofins Scientific group. He is currently Vice Chairman of Phú Thái Pharma and is a co-author of three peer-reviewed papers on probiotic strains of Bacillus subtilis.
Roles
Inogen Pty Ltd (Australia)
He is the founder of Inogen, which operates through Inogen Pty Ltd in Queensland, established in 2025. The company develops molecular diagnostic kits for sexually transmitted infections, antenatal Group B Streptococcus screening and male fertility testing.
Source: Australian Business Register
Phú Thái Pharma
Vice Chairman, Product Development and Financial Management.
Source: Phú Thái Pharma profile
GENTIS (Genetic Testing Service JSC), now Eurofins GENTIS
Member of the Board of Directors, 2022 to at least 2023. In February 2022, Eurofins Scientific announced its acquisition of GENTIS, and Sức Khỏe & Đời Sống, the newspaper of Vietnam's Ministry of Health, reported his election to the GENTIS board at the ceremony marking the company's entry into the Eurofins group. GENTIS listed him as a board member at its 13th anniversary in October 2023.
Sources: Sức Khỏe & Đời Sống, 10 February 2022; Eurofins, 9 February 2022; GENTIS, 13th anniversary
Tâm Việt Medical Equipment and Science Co. Ltd, Hanoi
Director and legal representative, from 2014 until at least 2020. The company supplied diagnostic equipment and reagents, including real-time PCR systems, to hospitals and laboratories in Vietnam.
Source: business registration record
Eramic Technology Era JSC
Co-author of research on the probiotic strains Bacillus subtilis Eramic 25 and Eramic 26, published in 2025 and 2026. The 2025 genome paper credits him with project administration and supervision and gives Eramic as his affiliation.
Source: PubMed Central
Research
Ngô Bá Bình's research activity concerns the characterisation and safety assessment of probiotic Bacillus subtilis strains isolated in Vietnam, undertaken with colleagues at Eramic Technology Era JSC. Between 2025 and 2026 the group published three peer-reviewed studies describing the genome and the in vitro safety profile of two strains, Eramic 25 and Eramic 26. His contribution to the genome study is recorded as project administration and supervision.
Genome report of a probiotic Bacillus subtilis strain isolated from healthy human feces in Vietnam
Le Thi H, Hoang Thi Thanh H, Dao Gia B, Doan Thi Thuy L, Luu Thi Thuy N, Nguyen Huu A, Bui Nhat L, Vuong Quang T, Dao Tuyet M, Ngo Ba B, Nguyen Vu T. Microbiology Resource Announcements. 2025;14(10):e00513-25. doi:10.1128/mra.00513-25. PubMed Central
This genome announcement reports the draft genome of B. subtilis strain Eramic25, isolated in 2022 from a stool sample collected from a healthy volunteer in Hanoi under ethics approval 637/QĐ-ĐHYHN. The genome was sequenced on the Illumina MiSeq platform and assembled de novo, yielding a 3,855,385 bp draft genome with a GC content of 43.53% and 4,247 predicted protein-coding sequences, and multilocus sequence typing assigned the strain to sequence type ST123. Screening for virulence determinants confirmed the absence of the major toxin genes bceT, hblABC, nheABC, cytK, entFM and cesB, supporting the strain's safety profile as a probiotic candidate. The sequence is deposited in GenBank under accession GCA_031932165.1.
Comprehensive in vitro assessment of the safety profile of Bacillus subtilis Eramic 25 and its potential for application in the development of functional foods and health supplements
Đoàn Thị Thùy Linh, Đào Gia Bách, Lưu Thị Thủy Ngân, Ngô Bá Bình, Hoàng Thị Thanh Hoa, Nguyễn Vũ Trung, Lê Thị Hội. Tạp chí Dinh dưỡng và Thực phẩm (Vietnam Journal of Nutrition and Food). 2025;21(3). doi:10.56283/1859-0381/892. OpenAlex
This study assessed the in vitro safety of B. subtilis Eramic 25 according to the Generally Recognised as Safe (GRAS) criteria of the United States Food and Drug Administration and the guidance of the European Food Safety Authority. The strain was tested for activity against pathogenic bacteria and for cytotoxicity in the Vero and HT-29 cell lines, and its genome was screened for virulence and antibiotic resistance genes. Eramic 25 showed no cytotoxicity in either cell line and carried no toxin-encoding or haemolysin genes, and its antibiotic resistance genes were not located on plasmids or mobile genetic elements, indicating a very low risk of antibiotic resistance gene transfer. The findings provide a basis for further studies in animals and clinical trials in humans.
Research and safety evaluation of the Bacillus subtilis Eramic 26 strain for application in probiotic production
Đoàn Thị Thùy Linh, Đào Gia Bách, Lưu Thị Thủy Ngân, Ngô Bá Bình, Hoàng Thị Thanh Hoa, Nguyễn Vũ Trung, Lê Thị Hội. Vietnam Journal of Science and Technology. 2026;68(2). doi:10.31276/VJST.2025.3525. VJST
This study evaluated the safety of B. subtilis Eramic 26 in accordance with GRAS guidance from the FDA and EFSA, through antibacterial activity testing against five indicator organisms (Escherichia coli, Salmonella Typhimurium, Enterococcus faecium, Staphylococcus aureus and Shigella flexneri), haemolysis and cytotoxicity assays in HT-29 and Vero cells, and genomic analysis of virulence and antibiotic resistance determinants. The strain showed no cytotoxic effect in either cell line. The resistance genes identified, including fosB, satA and ydhE/norM, together with mutations in gyrA and gyrB, were chromosomal and not associated with mobile genetic elements, and the strain carried genes for the bacteriocins bacilysin and subtilosin. The findings indicate that Eramic 26 is a safe strain with strong potential for application in probiotic production.
Professional profiles: LinkedIn · ORCID · Google Scholar
Last updated 19 October 2026